INS and metabolic syndrome: If left untreated, the progressive increase in insulin-resistant adipose tissue, particularly visceral fat, impairs insulin-mediated inhibition of lipolysis and, thus, increases circulating free fatty acids (FFAs), which promotes gluconeogenesis and lipogenesis in the liver that ultimately result in atherogenic dyslipidemia [6,8].